Welcome to our dedicated page for Petvivo Holdings news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on Petvivo Holdings stock.
PetVivo Holdings, Inc. (PETVW) reports developments tied to its veterinary biomedical device business and its PetVivo Animal Health and PetVivo AI subsidiaries. The company focuses on manufacturing, commercializing and licensing medical devices and therapeutics for companion animals, equines and equine athletes, including Spryng with OsteoCushion Technology and PrecisePRP.
Recurring news includes financial results, regulatory acknowledgements, investor presentations, product commercialization, licensing activity and updates on PetVivo.ai, an artificial intelligence platform for veterinary practice engagement. Company announcements also describe its strategy of adapting human therapies for animal-health applications and expanding commercial availability through veterinary and distribution channels.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has announced its participation as a Platinum Sponsor at the International Veterinary Academy of Pain Management (IVAPM) Pain Management Forum from April 2-4, 2023, in Atlanta, Georgia. The company will showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed to manage lameness and joint-related issues, particularly osteoarthritis. CEO John Lai emphasizes the forum as a crucial opportunity to present the benefits of SPRYNG to veterinary pain management experts. PetVivo is focused on the commercialization of innovative medical devices for companion animals and has a pipeline of seventeen products.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced the completion of the first cohort of a clinical study on Spryng™ with OsteoCushion™ Technology, targeting dogs with cruciate ligament injuries. Dr. Erik Kleeman presented these results at the Veterinary Orthopedic Society conference, highlighting a 64% response rate and a 51% mean pain score improvement in the cohort of 22 dogs. This study suggests that Spryng™ may serve as an effective option for managing lameness and joint conditions in companion animals. PetVivo aims to leverage human therapies for companion animal treatments efficiently.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) is showcasing its innovative product, SPRYNG™ with OsteoCushion™ Technology, at the Veterinary Orthopedic Society Annual Conference from March 11-18, 2023, in Big Sky, Montana. SPRYNG™ is an injection-based treatment targeting lameness and joint issues like osteoarthritis in companion animals. CEO John Lai expressed excitement for the opportunity to connect with veterinary professionals. Additionally, Dr. Erik Kleeman will present research on intra-articular injections for dogs with cruciate ligament injuries on March 17, 2023. PetVivo focuses on developing advanced biomedical devices for animal care, with a pipeline of seventeen products and nineteen patents.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) announced its participation in the Western Veterinary Conference from February 19-22, 2023, at Mandalay Bay, Las Vegas. The company will showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed for managing joint-related issues in pets, particularly osteoarthritis. The WVC is a key event, generally attracting over 15,000 veterinary professionals. CEO John Lai expressed optimism about discussing SPRYNG's benefits with veterinarians, evidencing the company's commitment to enhancing the quality of life for companion animals.
PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) reported significant financial results for Q3 of fiscal 2023, highlighting revenues of $510,109, a substantial increase from $51,004 in Q3 2022. This growth is attributed to the commercialization of its product, Spryng™ with OsteoCushion™ Technology, with $456,502 stemming from shipments to distributor MWI Animal Health. Despite increased revenues, the company's net loss for the quarter rose to $2,311,618 or ($0.23) per share, compared to ($0.17) per share last year, driven by increased operating expenses totaling $2,605,240.
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will report its financial results on February 9, 2023, after market close. A conference call is scheduled for 4:00 p.m. CT (5:00 p.m. ET) to discuss these results. Investors can access the live webcast through the company's Investor Relations website.
PetVivo focuses on innovative medical therapeutics for animals, with a product pipeline of seventeen offerings and nineteen patents protecting its technologies. The lead product, SPRYNG™ with OsteoCushion™ technology, targets joint-related afflictions in dogs and horses.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) is set to exhibit its innovative product, Spryng with OsteoCushion Technology, at the Minnesota Veterinary Medical Association Annual Meeting from February 2-4, 2023, in Minneapolis. Spryng is designed to manage lameness and joint issues like osteoarthritis in companion animals through an injectable veterinary medical device made from natural components. The company aims to leverage human therapies for animal treatment, showcasing a robust pipeline protected by nineteen patents. CEO John Lai invites attendees to visit their booth for insights on this veterinary advancement.
PetVivo Holdings, focused on companion animal health, will participate in the virtual Lytham Partners Investor Select Conference on January 31, 2023. CEO John Lai will present the company's innovative product, Spryng with OsteoCushion Technology, which is designed to manage joint issues like osteoarthritis in pets through an injectable delivery system. The conference will also include one-on-one meetings with management for investors. PetVivo has developed a range of biomedical devices and holds 19 patents to protect its technology. The company aims to accelerate the commercialization of its veterinary products, which are available for sale.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has announced its participation in the 2023 Lake Tahoe Equine Conference from January 23-27, 2023, held at Hyatt Lake Tahoe, Nevada. The company aims to showcase its innovative product, Spryng™ with OsteoCushion™ Technology, which is designed to manage lameness and joint issues in companion animals. This injectable veterinary medical device combines extracellular matrix particles to support damaged cartilage and address tissue defects. PetVivo's strategy focuses on leveraging human therapies for animal treatments, accelerating revenue timelines, and capitalizing on a portfolio of nineteen patents to protect its innovative biomaterials and methods.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will showcase its innovative veterinary medical device, Spryng™, at the 2023 FAEP Ocala Equine Conference on January 21-22, 2023, in Ocala, FL. The company aims to network with equine industry leaders to enhance its OsteoCushion™ Technology, which supports joint health in companion animals, particularly for osteoarthritis treatment. Spryng™ utilizes an injectable formulation of micronized extracellular matrix particles to assist in managing lameness and joint issues. PetVivo's strategy involves leveraging human medical innovations for quicker veterinary solutions.